Lakeshore Hospital Unlisted Shares
₹ 105
About Lakeshore Hospital Unlisted Shares
Are you looking to invest in a stable, high-growth healthcare asset with a strong brand presence in South India? Lakeshore Hospital & Research Centre (now VPS Lakeshore Hospital) is one of Kerala’s largest and most trusted multi-super-specialty hospitals. With world-class infrastructure, a growing medical tourism footprint, and solid financial fundamentals, it presents a compelling opportunity in the unlisted healthcare space.
A Legacy of Excellence:
-
Founded: 1996 by Dr. Philip Augustine; operational since January 2003 .
-
Location: NH-66 Bypass, Nettoor, Kochi, Kerala – strategically located with easy access to the airport and railway station .
-
Accreditations: NABH (National Accreditation Board for Hospitals) accredited, ensuring rigorous quality and patient safety standards .
-
Part of VPS Healthcare: Managed by the international VPS Healthcare group, which operates over 25 hospitals and 120 clinics across Europe, the Middle East, and India .
Infrastructure & Capacity:
-
Bed Capacity: Approximately 470–650 beds, making it one of the largest tertiary care hospitals in Kerala .
-
Advanced Facilities: Over 10 operation theatres, 43 intensive care units, 3T MRI, 64-slice CT scan, and a full digital imaging suite .
-
Unique Services: Air, water, and surface ambulance services (recognized by Limca Records), helipad, automated pharmacy, and 24/7 lab services .
Comprehensive Medical Specialties:
Lakeshore offers over 30 clinical departments, including:
-
Cardiology & Cardiovascular Surgery
-
Neurology & Neurosurgery
-
Oncology (Medical & Surgical)
-
Gastroenterology & Hepatology
-
Organ Transplantation: Liver, Kidney, and Bone Marrow Transplant programs. The hospital performed Kerala’s first living-donor liver transplant .
-
Orthopaedics: Joint replacement, sports medicine – introduced Kerala’s first robotic knee replacement system .
-
Nephrology & Urology, Pulmonology, Endocrinology, Pediatrics & Neonatology, Obstetrics & Gynecology, and more .
Awards & Recognition:
-
Guinness World Record: For the largest model of a human organ (‘HEART’ installation) .
-
Best Multispecialty Hospital in Kerala – Times Health Excellence Awards 2017 .
-
Best Hospital for Organ Transplantation – India Health Summit Awards 2019 .
-
Top Private Hospital in South India – CIMS Healthcare Excellence Awards 2020 .
-
Excellence in Patient Safety and Quality – NABH Awards 2022 .
Medical Tourism & International Patient Reach:
Lakeshore has a dedicated International Patient Division, assisting with visas, transfers, interpreters, and cashless insurance tie-ups. Foreign patient volume grew substantially – from ~6,008 in FY22 to ~20,047 in FY23, highlighting its growing appeal to patients from the Middle East, Europe, and Asia .
Financial Performance Overview (FY21-FY24):
The hospital has demonstrated strong financial discipline and growth:
| Particulars | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|
| Revenue (₹ Cr) | 242 | 359 | 419 | 396 |
| EBITDA (₹ Cr) | 32 | 83 | 102 | 73 |
| OPM % | 13.22% | 23.12% | 24.34% | 18.43% |
| PAT (₹ Cr) | 8 | 44 | 57 | 44 |
| NPM % | 3.31% | 12.26% | 13.60% | 11.11% |
| EPS (₹) | 0.80 | 4.40 | 5.70 | 4.40 |
Key Financial Ratios:
-
P/E Ratio: ~18.86x (as of recent data)
-
P/B Ratio: ~2.02x
-
Book Value: ₹41 per share
-
Debt to Equity: 0 (virtually debt-free)
-
ROE: 11%
Shareholding Pattern:
-
Dr. Shamsheer Vayalil Parambath (Chairman, VPS Healthcare): ~42.6%
-
Mr. Yusuff Ali M.A. (LuLu Group): ~18.8%
-
Other Investors: ~38.58%
Strengths & Growth Drivers:
-
Strong Brand & Clinical Excellence: Renowned for high-end specialties and complex procedures like organ transplants.
-
Growing Medical Tourism: Rising foreign patient inflow adds a high-margin revenue stream.
-
Diversified Revenue Base: Multi-specialty coverage ensures breadth and stability.
-
Promoter Strength: Backed by VPS Healthcare and marquee investor Yusuff Ali, providing credibility and scale.
-
Debt-Free Balance Sheet: Low financial risk and strong downside protection.
-
Research & Training: Runs DNB programs and clinical research, adding long-term value and cost synergies .
Risks & Considerations:
-
Liquidity Risk: As an unlisted company, shares trade over-the-counter (OTC) with limited daily liquidity. Exit via IPO or strategic sale is the primary realization event.
-
Regulatory Risk: Healthcare is subject to strict regulations; transplant programs can attract scrutiny.
-
Competition: Faces competition from other large chains like Amrita, Aster, and Apollo in South India.
-
Past Controversy: An organ donation case from 2009 led to criminal charges in 2023; while historical, it highlights ethical scrutiny risks in transplant medicine .
Valuation & Opportunity:
Currently, Lakeshore Hospital unlisted shares are available at approximately ₹103–110 per share , with a market capitalization of ₹830–1,350 crore . At a P/E of ~18–30x, it is reasonably valued for a stable healthcare play, especially given its debt-free status and strong institutional backing.
For investors seeking exposure to India’s growing healthcare and medical tourism story, Lakeshore Hospital offers a unique combination of clinical reputation, financial stability, and long-term growth potential.
Ready to Add a Premier Healthcare Asset to Your Portfolio?
Buy Unlisted Shares of VPS Lakeshore Hospital Ltd exclusively through Unlisted Network.
Invest in a trusted institution with a legacy of care, innovation, and financial strength.
Fundamentals
| Lakeshore Hospital Unlisted Share Price | ₹ 105 | Market Cap (in cr.) | ₹ 1050 |
| Per Equity Share | P/E Ratio | 26.92 | |
| Lot Size | 500 Shares | P/B Ratio | 2.43 |
| 52 Week High | ₹ 115 | Debt to Equity | 0 |
| 52 Week Low | ₹ 105 | ROE (%) | 9.24 |
| Depository | NSDL & CDSL | Book Value | 43.2 |
| PAN Number | AAACL4923A | Face Value | 10 |
| ISIN Number | INE01TI01010 | Total Shares | 100000000 |
| CIN | U85110KL1996PLC010260 | ||
| RTA | Integrated Registry Management Services |
Financial
| P&L Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 359 | 419 | 396 | 408 |
| Cost of Material Consumed | 102 | 112 | 111 | 117 |
| Change in Inventory | -2 | -2 | 2 | -0.2 |
| Gross Margins | 72.14 | 73.75 | 71.46 | 71.37 |
| Employee Benefit Expenses | 63 | 64 | 75 | 79 |
| Other Expenses | 113 | 143 | 135 | 141 |
| EBITDA | 83 | 102 | 73 | 71.2 |
| OPM | 23.12 | 24.34 | 18.43 | 17.45 |
| Other Income | 3 | 5 | 7 | 8.23 |
| Finance Cost | 2 | 2 | 1 | 0.3 |
| D&A | 22 | 23 | 24 | 26 |
| EBIT | 61 | 79 | 49 | 45.2 |
| EBIT Margins | 16.99 | 18.85 | 12.37 | 11.08 |
| PBT | 62 | 82 | 55 | 53 |
| PBT Margins | 17.27 | 19.57 | 13.89 | 12.99 |
| Tax | 18 | 25 | 11 | 14 |
| PAT | 44 | 57 | 44 | 39 |
| NPM | 12.26 | 13.6 | 11.11 | 9.56 |
| EPS | 4.4 | 5.7 | 4.4 | 3.9 |
Financial Ratios |
2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating Profit Margin | 23.12 | 24.34 | 18.43 | 17.45 |
| Net Profit Margin | 12.26 | 13.6 | 11.11 | 9.56 |
| Earning Per Share (Diluted) | 4.4 | 5.7 | 4.4 | 3.9 |
| Assets | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Fixed Assets | 340 | 328 | 347 | 343 |
| CWIP | 0 | 5 | 2 | 4.6 |
| Investments | 0 | 0 | 0 | 0 |
| Trade Receivables | 20 | 20 | 27 | 34 |
| Inventory | 11 | 13 | 11 | 11 |
| Other Assets | 93 | 134 | 121 | 140.4 |
| Total Assets | 464 | 500 | 508 | 533 |
| Liabilities | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Share Capital | 100 | 100 | 100 | 100 |
| FV | 10 | 10 | 10 | 10 |
| Reserves | 231 | 273 | 300 | 322 |
| Borrowings | 19 | 13 | 0 | 0 |
| Trade Payables | 33 | 34 | 33 | 39 |
| Other Liabilities | 81 | 80 | 75 | 72 |
| Total Liabilities | 464 | 500 | 508 | 533 |
| Cash-Flow Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| PBT | 59 | 82 | 55 | 53 |
| OPBWC | 87 | 114 | 74 | 74 |
| Change in Receivables | -56 | -29 | -13 | 2.9 |
| Change in Inventories | -2 | -2 | 2 | -0.2 |
| Change in Payables | 12 | -9 | 0 | 4.29 |
| Other Changes | 0 | 1 | 0 | 0.44 |
| Working Capital Change | -46 | -39 | -11 | 7.43 |
| Cash Generated From Operations | 41 | 75 | 63 | 81.43 |
| Tax | -10 | -20 | -19 | -13.12 |
| Cash Flow From Operations | 31 | 55 | 44 | 68.31 |
| Purchase of PPE | -26 | -9 | -46 | -22.6 |
| Sale of PPE | 1 | 0.1 | 0.5 | 0 |
| Cash Flow From Investment | -24 | -6.9 | -39 | -15.8 |
| Borrowing | -18 | -6 | -13 | 0 |
| Dividend | -5 | -15 | -17 | -17 |
| Equity | 0 | 0 | 0 | 0 |
| Others From Financing | -3 | -2 | -2 | -1 |
| Cash Flow from Financing | -26 | -23 | -32 | -18 |
| Net Cash Generated | -19 | 25.1 | -27 | 34.51 |
| Cash at the Start | 31 | 12 | 37 | 9.93 |
| Cash at the End | 12 | 37.1 | 10 | 44.44 |
